Hereditary Hemorrhagic Telangiectasia Clinical Trial
Official title:
Influence of Telangiectasia and Anemia on the Well-being and Quality of Life of Patients With Hereditary Hemorrhagic Telangiectasia (HHT).
Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler's disease, is a genetic disorder that leads to abnormal blood vessel formations. It primarily affects blood vessels in the skin, mucous membranes, and internal organs. The disease can be clinically diagnosed using the Curaçao criteria (1. Positive family history of HHT, 2. Recurrent and spontaneous epistaxis, 3. Multiple typical telangiectasias, 4. Organ involvement with vascular malformations, especially in the liver, lungs, gastrointestinal tract, or brain); if a patient meets at least 3 criteria, the diagnosis of HHT can be established. Patients with HHT often have telangiectasias on their faces. Additionally, many patients suffer from anemia, which can result in a pale and potentially tired appearance. Patients with HHT may be less satisfied with their appearance due to the aesthetic changes in their faces and may also experience psychosocial impairment. To further investigate this, various validated questionnaires (FACE-Q©, PROMIS-Profile-29+2, EQ5D), as well as routinely collected clinical data (e.g., laboratory values including hemoglobin levels, Curaçao criteria, smoking status, alcohol consumption, and the Epistaxis Severity Score (ESS)) will be used.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02874326 -
Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber
|
Phase 2 | |
| Completed |
NCT00389935 -
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
|
Phase 2 | |
| Active, not recruiting |
NCT04646356 -
Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)
|
Phase 2 | |
| Completed |
NCT04139018 -
Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia
|
Phase 2 | |
| Completed |
NCT03691142 -
Evaluation of Obstetrical and Neonatal Complications in Hereditary Haemorrhagic Telangiectasia (HHT)
|
||
| Recruiting |
NCT04404881 -
Bevacizumab In Hereditary Hemorrhagic Telangiectasia
|
Phase 2 | |
| Completed |
NCT02977637 -
MRA With Feraheme in HHT
|
Phase 1 | |
| Completed |
NCT01485224 -
Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia
|
Phase 2 | |
| Recruiting |
NCT06259292 -
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
|
||
| Active, not recruiting |
NCT04150822 -
Hereditary Hemorrhagic Telangiectasia (HHT) Research Outcomes Registry
|
||
| Recruiting |
NCT03850964 -
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
|
Phase 2/Phase 3 | |
| Completed |
NCT05752253 -
Counseling Intervention in Hereditary Hemorrhagic Telangiectasia in the COVID Era.
|
N/A | |
| Not yet recruiting |
NCT02458703 -
Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs With and Without Airflow Obstruction
|
N/A | |
| Completed |
NCT01752049 -
Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
|
Phase 1/Phase 2 | |
| Completed |
NCT00004649 -
Study of the Natural History and Genotype-Phenotype Correlations of Hereditary Hemorrhagic Telangiectasia Patients
|
N/A | |
| Active, not recruiting |
NCT04874558 -
Ultra-low-dose Chest CT for HHT
|
||
| Completed |
NCT01031992 -
Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
|
Phase 3 | |
| Recruiting |
NCT05269849 -
Sirolimus for Nosebleeds in HHT
|
Phase 2 | |
| Completed |
NCT03572556 -
Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT)
|
||
| Completed |
NCT04113187 -
Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients
|
Phase 3 |